As part of CMS’ movement to better healthcare, Sharecare aims to deliver immediate value to people through digital solutions that are secure, user-centered, and connected. Alongside other industry ...

Poursuite de l’amélioration des résultats et de la situation financière Le Conseil d’administration de Spineway, réuni le 30 juillet 2025 sous la Présidence de Stéphane Le Roux, a arrêté les comptes s ...

Ecully, July 30, 2025 – 7 p.m. The Board of Directors of Spineway, meeting on July 30, 2025 under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, ...

Choisir un équipement médical, ce n’est pas comme acheter n’importe quel objet/appareil. Derrière chaque dispositif, il y a ...

LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- UN Peace Ambassador Dr. Michael K. Obeng, the founder of Restore Worldwide, ...

Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the PFS curves compared to the control arm at a ...

FAITS SAILLANTS La généreuse contribution de la Fondation de la famille Slaight permettra à la Croix-Rouge d’offrir un soutien humanitaire aux personnes déplacées du Myanmar, en particulier les femmes ...

SupplyCopia's participation at AHRMM25 builds on the company's continued commitment to transforming healthcare supply chains through innovative AI solutions. The company's technology has helped health ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep ...

The Canadian Red Cross extends its gratitude to Gary Slaight and The Slaight Family Foundation for a $1 million contribution over two years, in support of humanitarian efforts in Cox’s Bazar, ...

Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD- (L)1 therapy ...